Baxter International Inc. announced sales results for the fourth quarter and full year of 2019. Worldwide sales in the fourth quarter totaled approximately $3.0 billion, an increase of 7% on a reported basis, 8%-9% on a constant currency basis and 9% on an operational basis. Operational sales exclude the impact of foreign exchange and generic competition for U.S. cyclophosphamide. Sales in the U.S. totaled approximately $1.3 billion and International sales totaled $1.8 billion.

Worldwide sales for the full year totaled approximately $11.4 billion, an increase of 2% on a reported basis and 5% on both a constant currency and operational basis. Sales in the U.S. totaled approximately $4.8 billion and International sales totaled $6.5 billion.

The company provided sales guidance for the full-year of 2020. For full-year 2020, the company expects net sales growth of 4% to 5% on both a reported and constant currency basis.